Nelli® is CE-marked as a class I medical device according to Directive 93/42/EEC.
Nelli® is commercially available in the EU.
Nelli® has been granted Breakthrough Device Designation by
the FDA and is an investigational device in the USA.
See
Fast and accurate seizure detection at home and in the hospital
Learn
Objective and easy-to-use data provided by AI and reviewed by a human expert
Improve
Better diagnostics and improved follow upNelli® analyses and quantifies motion and sound activity that suggest seizure behavior in adults and children.
Nelli® consists of a Personal Recording Unit (PRU) with camera and microphone, a cloud-based server for patient data analysis and a web-based dashboard for viewing the results remotely.
Video and audio recordings of the patient are captured at home or in a healthcare facility. Relevant motions and sounds are analysed by trained AI algorithms and lead to a interactive report and scattergram that can be reviewed by the physician.
Research supports accuracy of seizure detection
In a study comparing Nelli® to VEEG in 90 patients
-
86-100%
Sensitivity1
-
0.0-0.2
False positive rate1
1 Data on file, depends on seizure type
In a study with 99 patients, using Nelli® led to
-
91%
Significant clinical impact2
-
61%
Cost reduction2
-
82%
Changed treatment plans2
2 Data on file
